Targeted delivery of gene therapy for Alzheimer’s disease
Technology
EDGE-Tx is a precision gene therapy platform that selectively delivers therapeutic genes to the vulnerable neurons of the entorhinal cortex, where Alzheimer’s disease begins. By targeting only disease-relevant cells rather than expressing genes broadly across the brain, it improves precision while sparing healthy tissue. The platform is modular: targeting mechanism and therapeutic payload can be modified independently, enabling rapid adaptation across different gene therapies.
Market
There is no disease-modifying treatment for Alzheimer’s today, only symptomatic relief with serious side effects. The global Alzheimer’s therapeutics market is projected to grow to over $10 billion by 2035, with gene therapies positioned to capture a growing, multi-billion-dollar share.
Uniqueness
Conventional gene therapies distribute expression systemically, a major driver of immune responses and long-term safety concerns. EDGE-Tx instead confines expression to disease-relevant cells, delivering a markedly safer profile while its modular design allows the same platform to be redeployed across multiple therapies.
Status
- Seeking collaborators and licensees.
